Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma

N/AUnknownNCT03206866

Mansoura University96 enrolled

Overview

Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets. SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiﬁed from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\] Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative

Study Type

OBSERVATIONAL

Enrollment

Conditions

Role of Serum Regucalcin in Diagnosis of HCC

Interventions

serum regucalcin antibodyDIAGNOSTIC_TEST

serum regucalcin antibody

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy) 2. Adult patients 3. Both genders are eligible. 4. Informed consent obtained from subject or subject's legal representative Exclusion Criteria: 1. Patient with other malignancies. 2. Patients with advanced comorbidities except for renal failure. 3. Prior chemotherapy

Outcomes

Primary Outcomes

serum regucalcin in HCC patients

This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to: * evaluate its potential role as biomarker in diagnosis. * evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters.

Time frame: 1-12-2016 to 1-12-2017